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ABSTRACT The increasing clinical importance of human infections (frequently se-
vere) caused by Clostridium difficile PCR ribotype 078 (RT078) was first reported in
2008. The severity of symptoms (mortality of 30%) and the higher proportion of
infections among community and younger patients raised concerns. Farm animals,
especially pigs, have been identified as RT078 reservoirs. We aimed to understand
the recent changes in RT078 epidemiology by investigating a possible role for anti-
microbial selection in its recent evolutionary history. Phylogenetic analysis of inter-
national RT078 genomes (isolates from 2006 to 2014, n 400), using time-scaled,
recombination-corrected, maximum likelihood phylogenies, revealed several recent
clonal expansions. A common ancestor of each expansion had independently ac-
quired a different allele of the tetracycline resistance gene tetM. Consequently, an
unusually high proportion (76.5%) of RT078 genomes were tetM positive. Multiple
additional tetracycline resistance determinants were also identified (including efflux
pump tet40), frequently sharing a high level of nucleotide sequence identity (up to
100%) with sequences found in the pig pathogen Streptococcus suis and in other
zoonotic pathogens such as Campylobacter jejuni and Campylobacter coli. Each RT078
tetM clonal expansion lacked geographic structure, indicating rapid, recent interna-
tional spread. Resistance determinants for C. difficile infection-triggering antimicrobi-
als, including fluoroquinolones and clindamycin, were comparatively rare in RT078.
Tetracyclines are used intensively in agriculture; this selective pressure, plus rapid,
international spread via the food chain, may explain the increased RT078 prevalence
in humans. Our work indicates that the use of antimicrobials outside the health care
environment has selected for resistant organisms, and in the case of RT078, has con-
tributed to the emergence of a human pathogen.
IMPORTANCE Clostridium difficile PCR ribotype 078 (RT078) has multiple reservoirs;
many are agricultural. Since 2005, this genotype has been increasingly associated
with human infections in both clinical settings and the community. Investigations of
RT078 whole-genome sequences revealed that tetracycline resistance had been ac-
quired on multiple independent occasions. Phylogenetic analysis revealed a
rapid, recent increase in numbers of closely related tetracycline-resistant RT078
(clonal expansions), suggesting that tetracycline selection has strongly influenced
its recent evolutionary history. We demonstrate recent international spread of
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emergent, tetracycline-resistant RT078. A similar tetracycline-positive clonal ex-
pansion was also identified in unrelated nontoxigenic C. difficile, suggesting that
this process may be widespread and may be independent of disease-causing
ability. Resistance to typical C. difficile infection-associated antimicrobials (e.g.,
fluoroquinolones, clindamycin) occurred only sporadically within RT078. Selective
pressure from tetracycline appears to be a key factor in the emergence of this
human pathogen and the rapid international dissemination that followed, plausi-
bly via the food chain.
KEYWORDS Clostridium difficile, tetracycline resistance, whole-genome sequencing,
phylogenetic analysis, emerging pathogen, PCR ribotype 078
Clostridium difficile infection (CDI) is a significant international challenge, affectingpatients in community and health care environments worldwide (1–3). The severity
of symptoms ranges from mild diarrhea to pseudomembranous colitis and toxic
megacolon. Crude 30-day mortality in the United Kingdom is 16% (in a setting of
endemicity) and can exceed 30% (4, 5), while it has been estimated that almost half a
million CDIs caused 29,000 deaths in a single year in the United States (2).
The molecular epidemiology of CDI varies both temporally and geographically,
frequently in response to local antimicrobial prescribing (2, 6–8). Clinically important
outbreak-associated genotypes can emerge when the inherent resistance of C. difficile
to cephalosporins (9) is supplemented with acquired resistance to certain high-risk
antimicrobials, including clindamycin (10) and, more recently, fluoroquinolones. The
latter contributed to the emergence of multiple phylogenetically unrelated outbreak-
associated genotypes, including “hypervirulent” PCR ribotype 027 (11–13). However,
the reason(s) for the changing prevalence of other clinically important C. difficile
genotypes is frequently unknown (14).
The increased importance of C. difficile RT078 as a human pathogen was first
reported in The Netherlands, with CDI cases rising from 3% to 13% during 2005 to 2008
(15). Around the same time, a 10-fold increase was noted in North America (16). Similar
increases and occasional outbreaks were subsequently recorded throughout Europe
(17–19), and the incidence of C. difficile RT078 infections has recently increased to 4.4%,
9.7%, and 8.1% of total CDI cases in North America, England, and Scotland, respectively
(2, 20–22). Three distinctive features of RT078-associated CDI raise specific concerns,
namely, increased severity of disease with the highest genotype-specific mortality rate
(15, 23), a higher proportion of community-associated disease, and more infections in
younger age groups than by other genotypes (2, 12, 15, 24).
The agricultural association of C. difficile RT078 is reflected in its isolation from sick
and healthy animals (frequently pigs), bird droppings, vermin, and the farm environ-
ment (25–28). However, in common with many other toxin-producing C. difficile
genotypes, ribotype RT078 can be carried asymptomatically by human infants and
adults (29, 30). Isolates of RT078 recovered from humans and animals are genetically
very similar and can be identical (30). This genotype has also been isolated from a
variety of retail meat products, including pork, beef, and others (31, 32). Therefore, the
natural reservoirs of RT078 support the hypothesis that humans become colonized via
the food chain and/or the environment (25).
Whole-genome sequence data have been used to study the emergence and trans-
mission of many bacterial pathogens. The international dissemination of hypervirulent
fluoroquinolone-resistant C. difficile 027 was revealed in this way (12), and its rapid
localized nosocomial transmission was demonstrated, as with other fluoroquinolone-
resistant genotypes (8). Here, we used whole-genome sequencing and phylogenetic
approaches to study the recent evolutionary history of C. difficile RT078 and to inves-
tigate the hypothesis that the recent clinical prominence of this genotype has been due
to antimicrobial selection.
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RESULTS
The role of antimicrobial selection in the emergence of C. difficile RT078 was
investigated using a large (n 400), international collection of genomes from the
United Kingdom, Europe, and North America (see Table S1 in the supplemental
material) (8, 29, 30, 33, 34). Virtually all RT078 C. difficile strains share the same
multilocus sequence type (ST), ST11 (35). However, this ST also includes the very closely
related PCR ribotypes RT126, RT033, RT045, and RT066 (36) (the relationship to RT078
is shown phylogenetically in Fig. S1 in the supplemental material). Most of these
ST11-associated PCR ribotypes (RT033, RT045, and RT066) are relatively rare clinically,
with the possible exception of RT126 (18), which appears in our phylogeny to be
descended from (rather than predating) RT078 (Fig. S1). Only one of the RT078
genomes included was a single-locus variant of ST11, namely, ST317. The overall
proportion of RT078 within the collections from which the study genomes were
sourced (see Materials and Methods) was 3% to 4%, because these data sets are
dominated by RT027. The genomes studied are referred to here as RT078. The presence
of determinants of resistance to tetracyclines (tetM), fluoroquinolones (gyrA/B substi-
tutions), aminoglycosides [aphA1 or AAC(6’)-APH(2’)], and clindamycin (ermB) within
these genomes was assessed (Table 1 and 2).
Prevalence of antimicrobial resistance determinants in C. difficile RT078. tetM,
the presence of which leads to a tetracycline-resistant phenotype (30, 37, 38), was by
TABLE 1 Antimicrobial resistance accessory genes used to search C. difficile whole-genome sequencesa
Accessory gene
Reference
sequence
(GenBank) Protein encoded
Antimicrobial resistance
phenotype
(predicted)
tetMd NG_048243.1 Ribosomal protection protein Tetracycline
tetO AY394561.1 Ribosomal protection protein Tetracycline
tetW FR838948.1 Ribosomal protection protein Tetracycline
tetO/32/Ob AJ295238.3 Ribosomal protection protein Tetracycline
tetB(P) NG_048319.1 Ribosomal protection protein Tetracycline
tet40 JQ280445.2 Efflux pump Tetracycline
tetA(P) AB054980.1 Efflux pump Tetracycline
tetLc NG_048203.1 Efflux pump Tetracycline
ermBe HG002387.1 rRNA adenine N-6-methyltransferase Macrolide-lincosamide-streptogramin B (MLSB)
antibiotics, including clindamycin
aphA1f M26832.1 Aminoglycoside 3=-phosphotransferase Aminoglycoside (streptomycin)
AAC(6’)-APH(2’) M13771.1 6’-N-Acetyltransferase and 2-O-phosphotransferase
activities, bifunctional
Most clinically important aminoglycosides,
aAdditional classes of tetracycline resistance ribosomal protection proteins were searched for but not found, including those encoded by tet, otrA, tetS, tetQ, tet36, tetT,
and tet44 (75, 76). Additional tetracycline efflux pumps were searched for but not found, including those encoded by tetA, tetB, tetC, tetD, tetE, tetG, tetH, tetJ, tetV,
tetY, tetZ, tet30 (75).
bRibosomal protection protein gene mosaic (77).
cOnly found in ST54(012) (not RT078).
dtetM confers tetracycline resistance phenotype (30, 37, 38).
eMacrolide-lincosamide-streptogramin B (MLSB) resistance phenotype (conferred by the gene ermB) including clindamycin resistance, which has been associated with
CDI outbreaks (10, 78–80).
fAminoglycoside resistance as conferred by aphA1 (30).
TABLE 2 Antimicrobial resistance housekeeping genes used to search C. difficile whole-
genome sequences
Housekeeping
gene
Nonsynonymous
substitution
Protein
modified
Antimicrobial resistance
phenotype
gyrAa T(82)I DNA gyrase subunit A Fluoroquinolones
gyrBa D(426)N DNA gyrase subunit B Fluoroquinolones
rpoBb R(505)K  subunit RNA polymerase Rifampicin
aResistance to fluoroquinolones in C. difficile can be accurately predicted by the presence of the
nonsynonymous mutations in the following genes: gyrA C(245)T [T(82)I] and gyrB G(1276)A and [D(426)N] (8
[Table S1], 81–83).
bThe R(505)K substitution is the most frequently identified single substitution resulting in high-level
(32 mg/liter) resistance to rifampin (83, 84).
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far the most prevalent antimicrobial resistance determinant in RT078, at 77.5% (148/
191) among Oxfordshire and Leeds genomes, 76.4% (84/110) among Scottish genomes,
and 75.0% (24/32) among North American and European genomes (Table S1). gyrA/B
substitutions, which reduce susceptibility to fluoroquinolones, were less prevalent, at
13.0% (25/191) among Oxfordshire and Leeds RT078 genomes, 10.0% (11/110) among
Scottish RT078 genomes, and 18.9% (6/32) in North American and European RT078
genomes. Similarly, aphA1 (aminoglycoside resistance) was detected in 21.5% (41/191)
of the Oxfordshire and Leeds genomes, 9.1% (10/110) of the Scottish genomes, and
40.6% (13/32) of the North American and European genomes. Finally, ermB (clindamy-
cin resistance) occurred in 4.2% (8/191) of the Oxfordshire and Leeds genomes, 4.5%
(5/110) of the Scottish genomes, and 18.8% (6/32) of the North American and European
RT078 genomes. The co-occurrence of different resistance determinants (including
tetracycline resistance determinants) within RT078 was found to be variable (Table S1).
Prevalence of tetM in the clinical C. difficile population. To determine whether
the high level of tetM prevalence in RT078 was unusual among clinical C. difficile
isolates, all available additional genomes of other genotypes (defined by ST/PCR
ribotype) from the same isolate collections (except those comprising only RT078—the
Scottish [first described here] and Dutch [30] isolates) were examined for the presence
of tetM (Fig. 1A). The non-RT078 genotypes were described using the notation
FIG 1 Prevalence of tetracycline resistance determinants in RT078 and other clinically relevant C. difficile genotypes. (A) Proportion (percentage) of each
clinically important genotype that was positive for the ribosomal protection protein (RPP) gene tetM. Data are shown for genotypes having 10 genomes or more,
from isolate collections representing Oxfordshire (EIA positives and negatives, infant and farm) and Leeds, North America, and Europe (Optimer clinical trial)
(8, 29, 30, 33, 34). The total number of isolates of each genotype is shown above the bar. Clades are defined as described in reference 69. (B) Numbers of
genomes in the collections described above which contained additional non-tetM tetracycline resistance determinants. For the ST11(078) genotype, the
additional Scottish (n 110) isolate collection was also included (indicated by “110” above the bar at the left). Therefore, a total of 340 ST11(078) isolates
were examined (the n 230 described in the panel A legend above plus an additional n 110 Scottish ST11s), the aim being to illustrate the overall prevalence
of “non-tetM” tetracycline resistance determinants within this genotype.
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ST37(017) to indicate, for example, multilocus sequence type (MLST) 37 and the
equivalent PCR ribotype (017).
Genotypes could be classified as (i) 60% tetM positive, (ii) 0% but 20% tetM
positive (the majority being 5%), or (iii) tetM not detected (Fig. 1A). Non-RT078
genotypes were 20% tetM positive, with the notable exceptions of ST37(017) (52/80,
65.0%), ST54(012) (35/58, 60.0%), ST35(046) (27/39, 69.2%), and ST48 (8/12. 67.0%), plus
nontoxigenic ST26(140) (65/65, 100%) (Fig. 1A). Therefore, at over 75%, RT078 was the
most highly tetM-positive clinically relevant genotype.
Prevalence of additional tetracycline resistance determinants in the clinical C.
difficile population. Genomes were assessed for the presence of additional tetracy-
cline resistance determinants (Fig. 1B) (Table 1; see also Table S1). The tetracycline
efflux pump gene tet40 was present in 22.4% (76/340) RT078 (Fig. 1B; Oxfordshire,
Leeds, Optimer Europe and North America, and Scotland genomes; n 340, excluding
previously published Dutch genomes [n 60] because they had undergone prior
analysis for tetracycline resistance [30]; however, for completeness, they are included in
Table S1). Non-tetM ribosomal protection proteins were present in 6.5% (22/340) RT078
(Fig. 1B). In contrast to RT078, only one or two genomes of other ST/PCR ribotypes were
positive for alternative tetracycline resistance determinants, except ST54(012) (n 54),
in which eight examples of four additional tetracycline resistance determinants were
found, and ST33(216), which contained 10/25 (40%) tetAB(P) (Fig. 1B).
United Kingdom-representative RT078 phylogeny. A United Kingdom-specific
RT078 phylogeny was constructed using genomes from clinical infections in Oxford-
shire (n 78), the Leeds region (n 104), and Scotland (n 110) (Fig. 2A and B; see
also Table S1). Annotation revealed minimal evidence of geographic structure, con-
trasting markedly with the highly structured distribution of tetM sequences (Fig. 2B and
C) described in detail below (maximum likelihood [ML] phylogeny obtained before
dating also supplied; see Fig. S2).
Prior to annotation, distinct tetM allele sequences were assigned a number (available
at https://pubmlst.org/bigsdb?dbpubmlst_cdifficile_seqdef&pagedownload
Alleles). Among the tetM-positive United Kingdom RT078 genomes, the following three
tetM alleles predominated: tetM 10 (36/292, 12.3%), tetM 16 (101/292, 34.6%), and tetM
19 (78/292, 26.7%) (Fig. 2B). Colored bars (Fig. 2B) (or branches in Fig. S1) were used to
identify distinct tetM alleles. Each of tetM alleles 10, 16, and 19 were carried by closely
related, Tn916-like conjugative transposons (well-established Gram-positive tetM-
carrying mobile elements) (37). Independent acquisition events, estimated from the
phylogeny to have occurred between 1995 and 2006, were suggested by their unique
chromosomal insertion sites (Fig. 2B, circular map) and by the level of nucleotide
sequence identity across the Tn916-like elements on which they were carried (87% to
100%, depending on the region compared) (Fig. S3). Acquisition of tetM 16 or tetM 19
was associated with significantly shorter branch lengths (confirmed by median evolu-
tionary distinctiveness [ED] scores of 3.78 and 3.58, respectively, versus 7.22 for
branches representing genomes lacking a ribosomal protection protein gene;
P 0.001). This observation is consistent with the presence of clonal expansion in
response to tetracycline-associated selection pressure (Fig. 2B and C); significantly
lower ED scores indicate unexpectedly short branches (39). It is possible that, for a given
branch, there could be some genetic change other than tetM that was the cause of the
clonal expansion, but since the same pattern was observed on several independent
branches where tetM was acquired, each time within a different Tn916 variant (Fig. S3),
it seems very likely that this underlies the clonal expansion. The acquisition of efflux
pump tet40 on its own was not associated with clonal expansion, with only a slightly
higher median evolutionary distinctiveness score than was calculated for tet40 absence
(Fig. 2C).
The same phylogeny was annotated for the presence of additional resistance
determinants (conferring aminoglycoside, fluoroquinolone, or clindamycin resistance;
Tetracycline Selection in C. difficile RT078 ®
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FIG 2 United Kingdom-representative, time-scaled RT078 phylogeny revealing a lack of geographic structure but strong structuring of tetracycline
resistance. (A) Map showing the areas of the United Kingdom from which the RT078 C. difficile genomes were obtained. (B) Time-scaled ClonalFrameML
phylogeny constructed using genomes from United Kingdom C. difficile isolates, comprising Oxfordshire (n 78), Leeds (n 104), and Scottish (n 110)
isolates. Branch colors, as defined for panel A, denote the location of each genome. Colored bars to the right of the phylogeny indicate the presence of
tetracycline resistance determinants; ribosomal protection protein (RPP) allele sequences detected within each genome were assigned numbers to identify
distinct nucleotide sequences of tetM, tetO/32/O, tetO, or tetW. To the right of the phylogeny, the chromosomal locations of the three most prevalent tetM
alleles (designated tetM 10, 16, and 19) relative to the RT078 M120 genome (NCBI reference sequence NC_017174.1) are shown. All phylogenies included
in this study are directly comparable post-1990, i.e., in the time frame of RT078 emergence; the gray shaded block over the region corresponding to the
time period prior to that date indicates that region is not scaled identically and should not be used for comparisons. (C) The extent to which RT078 clonal
expansions are associated with geographic structure and tetracycline resistance (ribosomal protection proteins and efflux pumps) was determined using
two-sided quantile regression. (Left) Differences in median evolutionary distinctiveness scores compared to Oxfordshire samples. A lower evolutionary
distinctiveness value indicates a larger proportion of close relatives in the tree. The P values indicate the overall significance of geographic location in the
evolutionary distinctiveness score. (Center) Differences in median evolutionary distinctiveness scores for samples with ribosomal protection proteins
detected compared to ribosomal protection protein-negative samples, overall and for each of the three putative tetM-associated clonal expansions. A lower
evolutionary distinctiveness value indicates a larger proportion of close relatives in the tree. The P values indicate the significance of gene presence in the
evolutionary distinctiveness score. (Right) Differences in median evolutionary distinctiveness scores for samples with tetracycline efflux pumps [tet40 and
tetA(P)] detected compared to efflux pump-negative samples. A lower evolutionary distinctiveness value indicates a larger proportion of close relatives in
the tree. The P value indicates the significance of gene presence in the evolutionary distinctiveness score.
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Fig. S4A to C), but no evidence of associated clonal expansions occurring indepen-
dently of the tetM-associated expansions was found (Fig. S4D to F).
RT078 phylogenies representing United Kingdom regions. Separate phylogenies
were constructed to examine the detailed evolutionary history of RT078 within two of
the geographic regions represented in the United Kingdom phylogeny. The two
regions were Scotland (population, 5.295 million; area, 30,918 square miles) (Fig. 3A and
B) and Oxfordshire (population, 655,000; area, 1,006 square miles) (Fig. 3A and C) (ML
phylogeny obtained before dating also shown; Fig. S2).
The branches of the Scottish phylogeny (n 110 genomes; Fig. 3B) were colored to
represent geographic regions (administrative areas, or “health boards”; Fig. 3A), thus
increasing the level of geographic discrimination. As described above, geographic
structure was absent, with health care-associated and community isolates intermin-
gling (Fig. 3B, dots), but the distribution of the tetM alleles 10, 16, and 19 within the
phylogeny was highly structured.
The Oxfordshire regional phylogeny (n 94 genomes, Fig. 3C) represented a more
densely sampled, smaller geographic area (Fig. 3A). Here, the enzyme immunoassay
(EIA)-positive C. difficile clinical isolate genomes (n 78; Fig. 2B) were supplemented
with EIA-negative clinical isolates (n 9) (i.e., isolates from patients with diarrhea but
without evidence of toxin production, suggesting that C. difficile was colonizing the
patient rather than causing disease) and nonclinical isolates from healthy infants (n 6)
(29) and a lamb (n 1) (Table S1). All genomes were pathogenicity locus (PaLoc) (i.e.,
toxin A and B encoding sequence) positive (40). This regional phylogeny also lacked
structure according to location or isolation source, but it was again structured accord-
ing to tetM allele (Fig. 3C).
International phylogenies confirmed that three tetM-positive RT078 clades are
present across continents. Two international RT078 phylogenies were constructed
using genomes from clinical infections in England (Oxfordshire [n 78] and Leeds
[n 104]) supplemented first with clinical and nonclinical isolates from The Nether-
lands (30) (Table S1; clinical isolates from humans [n 25] and isolates collected from
farmers [n 15] and pigs [n 20]) (Fig. 4A and B), and second with genomes from
clinical infections in North America (Table S1; United States [n 15], Canada [n 4])
and Europe (five countries [n 13]) (Fig. 4C and D). Once again, structure according to
geography was absent, but structuring by tetM allele (Fig. 4B and D) was clear (ML
phylogeny obtained before dating also shown; see Fig. S2).
Tetracycline selection in other C. difficile genotypes. Over 60% of genomes
belonging to each of five non-RT078 genotypes were tetM positive (Fig. 1A). Four of
these were investigated phylogenetically, namely, ST37(017), ST54(012), ST35(046), and
nontoxigenic ST26(140) (8, 29) (Table S2), but not ST48(038/104), as only 12 genomes
were available. Branches were colored according to isolation source and geography as
described above, and tetM alleles are indicated by colored bars (Fig. 5). As described
above for RT078, additional resistance determinants (Table 1 and 2) were also high-
lighted (when present in five genomes or more) to reveal the possible impact of
selection by other antimicrobials (Fig. 5, colored dots) (ML phylogeny obtained before
dating also shown; Fig. S2).
A number of recent tetM acquisition events were obvious (Fig. 5). These were
followed by possible clonal expansions, most notably within genotypes ST35(046) and
(nontoxigenic) ST26(140) (Fig. 5A and B). Clonal expansion was particularly marked in
ST26(140), where all genomes were tetM positive, and clonal expansion occurred in the
absence of disease-causing ability, this genotype being nontoxigenic (lacking the
pathogenicity locus [PaLoc] in all genomes [40]). With the exception of ST35(046),
where aminoglycoside and clindamycin resistance determinants colocalized with tetM
(Fig. 5A), and the fluoroquinolone-resistant region of the ST37(017) phylogeny (Fig. 5D)
(8), there was no clear evidence of the clonal expansions which had followed the
acquisition of the non-tetM antimicrobial resistance determinants. In common with
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RT078, all four phylogenies (Fig. 5) lacked geographic structure, with the exception of
the fluoroquinolone resistance region of the ST37(017) phylogeny (Fig. 5D) (8).
Sequences of RT078 tetracycline resistance determinants support the hypoth-
esis of its zoonotic origin. The tetM sequences in C. difficile described here are typical
FIG 3 United Kingdom regional RT078 phylogenies; Scotland and Oxfordshire. (A) Map and legend indicating the regions of Scotland and Oxfordshire from
which genomes originated. The Scottish regions correspond to administrative areas known as “health boards.” (B) Time-scaled RT078 phylogeny for Scotland.
Branch colors are as described in the panel A legend. Colored bars to the right of the phylogeny denote the ribosomal protection protein (RPP) allele sequences
detected within each genome (as described in the Fig. 2 legend), numbers being assigned to identify distinct nucleotide sequences of tetM or tetO/32/O. Isolates
were cultured from human clinical samples received from both hospital and community patients, the latter being indicated by a black dot. The gray shaded
block over the region corresponding to the period prior to 1990 indicates that the region is not scaled identically for different phylogenies and should not be
used for comparisons. (C) Time-scaled RT078 phylogeny for Oxfordshire clinical and nonclinical isolates. Branch colors are as described in the panel A legend.
Colored bars indicate ribosomal protection protein alleles as described above.
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FIG 4 International phylogenies confirm that three major tetM-positive RT078 clades are present across continents. (A) Map of Western Europe. The
regions of England and The Netherlands from which the genomes included in panel B originated are highlighted (in black and pink, respectively). (B)
Time-scaled RT078 phylogeny constructed using genomes of clinical isolates from England (Oxfordshire and Leeds), supplemented with genomes from
the Netherlands (human isolates [clinical or farmer] and pig isolates [30]). Branch colors are as described for the map in panel A. The presence of the
three predominant ribosomal protection protein (RPP) tetM alleles (tetM 10, 16, and 19) is indicated by the colored bars to the right of the tree. The gray
shaded block over the region corresponding to the period prior to 1990 indicates that the region is not scaled identically for different phylogenies and
should not be used for comparisons. (C) Map highlighting the regions in North America and Western Europe from which the genomes included in panel
(Continued on next page)
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of many Gram-positive species, including established zoonotic species. For example,
the RT078 tetM 10 allele shared 100% nucleotide sequence identity with tetM genes of
Streptococcus agalactiae, Enterococcus faecalis, Escherichia coli, and Streptococcus pneu-
moniae and 99% nucleotide sequence identity with Streptococcus suis (a pathogen of
pigs transmitted zoonotically to humans [41, 42]). Identical tetM 10 sequences have also
been found in Gram-negative bacterial species, including Escherichia coli. The RT078
FIG 4 Legend (Continued)
D originated. (D) Time-scaled RT078 phylogeny constructed using genomes of clinical isolates from England supplemented with clinical isolates from
North America and Europe (distinct from the isolates used as described for panel B) from two clinical trials of the drug fidaxomicin (Table S1) (33, 34).
FIG 5 Phylogenetic analysis of additional tetM-positive C. difficile genotypes. Time-scaled phylogenies were constructed representing four non-RT078
genotypes with 60% tetM prevalence as follows: (A) ST35(046), (B) ST26(140), (C) ST54(012), and (D) ST37(017). In the phylogenies shown in panels B and D,
a single closely related genome of a distinct genotype (ST12 and ST109, respectively) was included to ensure that the tree was rooted pre-1990 and that the
four phylogenies could therefore be compared post-1990. The gray shaded block over the region corresponding to the period prior to 1990 indicates that the
region is not scaled identically for different phylogenies and should not be used for comparisons. Genomes were from Oxfordshire (clinical EIA positives and
negatives plus nonclinical, healthy infants) and Leeds (clinical isolates); branch colors indicate location/isolation source as described above. Colored bars to the
right of each phylogeny indicate the presence of tetracycline resistance determinants. Colored dots represent additional genetic determinants identified as
conferring resistance to fluoroquinolones, rifampin, clindamycin, and aminoglycosides (Table 1 and 2) and are shown where five or more positive genomes were
identified per genotype.
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tetM 16 allele shared 97% nucleotide sequence identity with tetM in Enterococcus
species (mostly E. faecalis and E. faecium), followed by Staphylococcus and Streptococcus
species, including S. suis.
Other RT078 tetracycline resistance determinants were also identical or were very
closely related to those found in bacteria with an agricultural association which may be
zoonotic. For example, RT078 tet40 sequences shared 99% to 100% identity with
Streptococcus suis tet40 (GenBank accession no. KC790465.1) and the RT078 tetO
sequences shared over 99% nucleotide sequence identity with Campylobacter jejuni,
Campylobacter coli, and S. suis tetO sequences. In addition, the RT078 tetO/32/O mosaic
sequence shared 99% identity with the sequence found in the S. suis genome.
DISCUSSION
Our time-scaled phylogenies revealed geographically unstructured, parallel tetM-
associated RT078 clonal expansions, dating from around the year 2000 (Fig. 2B, 3B and
C, and 4B and D). These findings are consistent with an evolutionary response to
tetracycline selective pressure, within the milieu of tetracycline-resistance determi-
nants, during the time frame of increasing numbers of RT078-associated clinical cases
(15, 18–20, 22). The results from our use of whole-genome sequence-based phylogenies
explained the prior observation (using multilocus variable-number tandem-repeat
analysis [MLVA] [38]) that the majority (85%) of human and porcine RT078 genomes are
genetically related, irrespective of the European country of origin, since we showed that
most RT078 genomes are recent descendants from one of three distinct (but closely
related and now internationally disseminated) tetM-positive ancestral RT078 genomes
(Fig. 2 to 4).
Tetracyclines were initially introduced around 60 years ago in both clinical and
veterinary settings. However, following the emergence of resistance, they were largely
replaced in human medicine by fluoroquinolones (43). Consequently, by 2010 to 2013,
tetracyclines represented a total of 18% of the antibiotics consumed by patients in
England, and most (92%) were prescribed in the community by general practitioners
(44). Over the time period relevant to this study, tetracyclines were most commonly
used for the treatment of acne and chlamydial sexually transmitted diseases. It is
implausible that such prescribing in teenagers and young adults provided extensive
selection pressure for C. difficile, given that healthy individuals living in the community
have very low rates of colonization by these bacteria (45).
In contrast to their use in human medicine, tetracyclines remain the most widely
used antimicrobial for the treatment, control, and prevention of infections in animals
(46). In addition, their use for growth promotion (in subtherapeutic doses) continues
around the world, if not overtly, under the guise of disease prevention. This is the case
despite the fact that growth promotion is banned in Europe (47) and that claims of
growth promotion have been voluntarily removed by drug companies in the United
States at the request of the FDA (January 2018). During 2015, 6,880 metric tons of
tetracyclines were sold in the United States (48) (representing a 31% increase from
2009), compared to 166 tons in the United Kingdom (49). The extent of agricultural
tetracycline use, the prevalence of RT078 in animals used for food (25, 26, 31, 32, 38),
and the time frame of RT078 emergence all implicate tetracycline use in agriculture as
a plausible source of selective pressure. The global food chain, including, for example,
regionally concentrated livestock production followed by widespread distribution of
meat products, represents an obvious route for rapid RT078 dissemination (food and
livestock RT078 genomes/isolates are listed in references 25 and 50), which would be
consistent with our phylogenies (Fig. 2 and 4). However, indirect transmission from the
agricultural environment to humans via contaminated water or vegetables (51) is also
a possibility. Our report provides evidence of a plausible agricultural link underlying the
emergence of RT078 by presenting its recent evolutionary history with respect to the
acquisition of antimicrobial resistance.
The absence of geographic structure within our RT078 phylogenies is consistent
with its rapid international spread (Fig. 4) as described previously (38, 50) and with the
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lack of large-scale, localized nosocomial RT078 outbreaks (Fig. 2B, 3B and C, and 4B and
D). Among other genotypes, such outbreaks have been associated with extensive
prescribing of, and resistance to, high-risk antimicrobials such as clindamycin, cepha-
losporins, and fluoroquinolones. In our study, large-scale clonal expansions were not
associated with fluoroquinolone or clindamycin resistance in RT078 genomes (see
Fig. S4 in the supplemental material). Equivalent analyses for cephalosporins cannot be
performed because the genetic mechanism(s) of cephalosporin resistance in C. difficile
has yet to be defined, and, although MICs can vary, C. difficile has typically been
considered inherently cephalosporin resistant, irrespective of genotype (9). The inter-
national spread of RT078 indicates that changes in antimicrobial resistance phenotypes
could potentially have an impact at any location, depending on local prescribing
practices. Consequently, RT126, a frequently isolated fluoroquinolone-resistant descen-
dant of RT078 (Fig. S1, phylogenetic context), which is prevalent in Italian clinical
settings (52, 53), is of particular concern, as is the epidemic multidrug-resistant RT078
observed in Spanish swine (54).
Tetracyclines (such as doxycycline) are associated with a lower risk of CDI in humans
(55) than has been established for many antimicrobials. It has been proposed (55) that
the use of tetracyclines as an alternative to riskier antimicrobials such as fluoroquino-
lones and clindamycin, whenever appropriate, may decrease CDI associated with
antibiotic use. However, the emergence of tetracycline-resistant C. difficile genotypes
such as RT078 and others (Fig. 5) may require this approach to be informed by
resistance data for the infecting strain, to avoid triggering tetracycline-resistant CDI.
Tetracyclines may be unrecognized as a potential CDI risk factor, since resistance
emerged relatively recently (with respect to RT078) and is less common at the popu-
lation level (Fig. 1A); clindamycin-resistant and fluoroquinolone-resistant strains in
particular predominate under outbreak conditions (10–12).
The identification of widespread tetracycline resistance (60% tetM positive) in only
five C. difficile genotypes in addition to 078 (Fig. 1A) is consistent with previous reports
(17, 56, 57). Phylogenetic analysis showed that ST35(046) contained two plausible
tetM-associated clonal expansions (Fig. 5A), but the relatively small numbers precluded
quantitative evolutionary distinctiveness analysis. Like RT078, ST35(046) has been
found in pigs and has caused human outbreaks of CDI (58). This genotype also
illustrates the possibility that selection by one antimicrobial can drive the acquisition of
further, linked resistance genes, as almost every tetM-positive ST35(046) genome was
also positive for clindamycin and aminoglycoside resistance determinants (Fig. 5A).
Nontoxigenic ST26(140) contained tetM in every genome examined, suggesting stable
integration predating a recent clonal expansion (Fig. 5B) concurrent with that of RT078.
ST26(140) therefore illustrates the possible consequences of tetracycline selection in a
harmless commensal organism, confirming that tetracycline selection alone may have
been sufficient to drive the emergence of RT078.
The hypothesis that RT078 has an agricultural origin is further supported by the
observation that RT078 shares many resistance determinants with zoonotic pathogens
such as Streptococcus suis, Campylobacter jejuni, and C. coli, suggesting a common
reservoir (see Results). Quantitative analysis (Fig. 2C; see also Fig. S4E and F) confirmed
that tetM was associated with RT078 clonal expansions. Although widespread in RT078,
the tetracycline efflux pump tet40 did not show such an association on its own (Fig. 2B
and C). Efflux pumps often confer a low-level-resistance phenotype, assisting bacterial
survival at sublethal concentrations of antimicrobials (for example, tetK in livestock-
associated methicillin-resistant Streptococcus aureus [LA-MRSA] CC398 [59]). They
thereby function in promoting the acquisition of further high-level-resistance determi-
nants, such as tetM. The parallels between RT078 and zoonotic Streptococcus suis also
extend to their epidemiology. S. suis is a globally distributed emergent pathogen of
humans (42), commonly isolated from pigs. Geographic clustering of subpopulations
is absent (41), and S. suis has exhibited rapid, recent increases in tetracycline
resistance (59). The emergence of human pathogens, coincident with tetracycline
resistance acquisition, has also been noted among other bacterial species. Tetra-
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cycline resistance in group B streptococci may have contributed to its emergence
as a leading cause of human neonatal infections (60). In a study examining LA-MRSA
S. aureus CC398 isolates, almost all were found to be tetM positive, and many were
also found to carry the tetK (efflux pump) gene (61).
Although multiple lines of evidence indicate a role for tetracycline selection in the
recent evolutionary history of RT078, the possibility exists that further lineage-specific
genetic changes (unrelated to tetracycline resistance) contributed to its tetM-associated
clonal expansions (Fig. 2 and 4; see also Fig. S2). A recently proposed hypothesis is that
an enhanced ability to metabolize the disaccharide trehalose (conferred by a specific
four-gene chromosomal insertion) helped to drive the emergence of C. difficile RT078
in humans (62) due to the introduction of trehalose as a food additive. The authors of
that study identified the same gene cluster in closely related non-078 clade 5 (clades
defined as described in reference 35) PCR ribotypes (033, 045, 066, and 126). Therefore,
the possibility that the insertion occurs throughout clade 5 or, indeed, among the other
four C. difficile clades was not excluded. The trehalose and tetracycline hypotheses are
not mutually exclusive. However, the available evidence suggests that tetracycline
resistance driven by tetM acquisition remains the most plausible available explanation
for the recent clonal expansions observed in RT078.
The role of selection by antimicrobials other than tetracycline (fluoroquinolones,
clindamycin, aminoglycosides) was investigated (Fig. S4), and a small potential contri-
bution by aminoglycosides (also used in animal production) was indicated by the
presence of the aphA1 resistance gene in a minority of RT078 genomes (Fig. S4A).
However, aphA1 could not be assessed independently of tetM (Fig. S1) because the two
genes colocalized. Further work would be required to compare the total gene content
of tetM-positive RT078 isolates with that of older tetM-negative isolates to identify
further potentially relevant genetic differences that could explain the clonal expan-
sions. The identification of tetM-associated clonal expansions in genetically divergent C.
difficile genotypes, ST35(046) (together with clindamycin and aminoglycoside resis-
tance determinants; Fig. 5A) and nontoxigenic ST26(140) (Fig. 5B), serves to further
highlight tetM as a factor common to recent clonal expansions within distinct C. difficile
genetic backgrounds. To further confirm the zoonotic origin of RT078 and the link to
agricultural tetracycline use, large-scale, parallel data showing changing tetracycline
use over time and concurrent RT078 isolates from clinical cases and farm animals would
be required. Although it would be challenging to source both usage data and corre-
sponding isolate collections retrospectively, evidence of phylogenetic coclustering of
human and animal RT078 genomes has been provided both nationally and interna-
tionally (30, 50), using collections assembled as available from other studies and
reference laboratories.
In summary, numerous lines of evidence described in this and prior work (25, 30, 50)
support the hypothesis that tetracycline use in agriculture has provided recent selec-
tion pressure which has impacted on the evolution of tetracycline-resistant RT078. This
in turn supports the hypothesis (first proposed in 2012 [25]) that humans become
colonized by RT078 via the food chain and/or the environment. Recent studies using
whole-genome sequencing of 65 Dutch RT078 isolates and 248 international RT078
isolates (30, 50) provided data consistent with the rapid spread of RT078 both inter-
nationally and between animals and humans. Furthermore, a range of tetracycline-
resistant determinants were described in both human and animal RT078 populations,
including tetM, tet40, tet32, tet44, and tetO (30, 50). Our findings independently confirm
and extend this work, since we demonstrate at least three independent clonal expan-
sions of RT078, with rapid international spread, following unconnected tetM acquisition
events (tetM carried on distinct Tn916 variants inserted into distinct chromosomal
locations; Fig. S3) which occurred in well-separated regions of the RT078 phylogeny
(Fig. 2 to 4). We also show that the RT078 genome is almost unique within the C. difficile
population as a whole, in terms of the diversity of its tetracycline resistance determi-
nants (Fig. 1). The major C. difficile RT078 transmission routes to humans are conse-
quently more likely to be related to agriculture and international food chains than
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nosocomial. Our findings add to the body of evidence (50) supporting initiatives such
as “One Health” (63). Our findings strongly suggest that the use of tetracycline outside
the health care environment has impacted several C. difficile genotypes, most strikingly
RT078, and therefore has not only selected for resistant organisms but also contributed
to the emergence of this species as a human pathogen.
MATERIALS AND METHODS
C. difficile whole-genome sequences. C. difficile genomes derived from isolates of either RT078 or
ST11 (n 400) were sourced from several published collections (8, 29, 30, 33, 34), as well as from an
unpublished Scottish collection and the Oxford University farm, Wytham, United Kingdom (see items i to
v below and Table S1 in the supplemental material). Each isolate was obtained from a distinct sample.
EIA-negative isolates were inferred to be toxigenic or nontoxigenic, depending on the presence/absence
of the toxin-encoding pathogenicity locus (PaLoc) (40) (Tables S1 and S2). The complete collections
described in sections i, iii, and iv below have been published previously (8, 29, 30).
(i) Clinical C. difficile: Oxfordshire and Leeds, United Kingdom. Genomes were available for 87
RT078 or ST11 C. difficile isolates cultured from symptomatic Oxfordshire patients by the Clinical
Microbiology Laboratory, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, between
September 2006 and April 2013 (8). Seventy-eight isolates were derived from toxin enzyme immunoassay
(EIA)-positive stools (initially [i.e., until April 2012] by the use of the Meridian Premier Toxins A&B Enzyme
Immunoassay [Meridian Bioscience Europe, Milan, Italy] and subsequently by the use of the TechLab Tox
A/B II assay [TechLab Inc., Blacksburg, VA, USA]) and 9 from EIA-negative but glutamate dehydrogenase
(GDH)-positive samples (by the use of Premier C. difficile GDH EIA [Meridian Bioscience Europe, Milan,
Italy]) (8). Genomes were also available for 104 RT078 C. difficile-positive stool samples (identified using
cytotoxin testing) obtained from routinely examined diarrheal fecal samples at the Leeds Teaching
Hospitals NHS Trust between August 2010 and April 2013 (Table S1).
(ii) Clinical C. difficile: Scotland, United Kingdom. The isolates from Scotland, United Kingdom,
included 109 isolates of RT078 and 1 closely related RT066 isolate (Table S1). These isolates form part of
a collection stored at the Scottish Microbiology Reference Laboratory (Glasgow). Cultures are provided
by Scottish regional NHS Healthcare Boards (located per the map shown in Fig. 3A) in the event of a
severe/fatal case, a suspected outbreak, or a suspected ribotype 027 infection. In addition, each Health
Board provides a fixed number of samples based on the rates of infection/population. This allows
surveillance of prevalent circulating strains to be assessed. RT078 isolates for this study were selected
based on the ribotypes from samples referred to the Reference Laboratory between November 2007 and
October 2014 and with the aim of providing the widest temporal and geographical representation.
Locally, positive fecal stool samples were identified prior to 2009 using a toxin-specific EIA (or cell
cytotoxicity) and post-2009 by the use of a two-step algorithm requiring GDH detection, followed by
toxin assessment. These samples were from patients located in health care (n 99) and community
(n 10) settings (unassigned n 1) in 12 of 14 Health Boards (there were no relevant samples from 2
small-island Health Boards [not shown in the map in Fig. 3A]).
(iii) Clinical C. difficile: North America and Europe. Thirty-two ST11 genomes from North American
(Canada, n 4; United States, n 15) and European (n 13) C. difficile isolates cultured from clinical
infections between November 2006 and June 2009 were available from a variety of locations from two
clinical trials of fidaxomicin (Table S1, showing city and country [33, 34]). Previously published RT078
genomes from human clinical cases (n 25; 2002 to 2011) in The Netherlands were also included (30)
(Table S1).
(iv) Nonclinical C. difficile. Six ST11 isolates were cultured from the stools of healthy, asymptomatic
Oxfordshire infants (29) between April and October 2012 (Table S1). A single ST11 isolate was isolated
from a lamb at Oxford University Farm, Oxfordshire, United Kingdom, in June 2009. Previously published
C. difficile RT078 genomes from farmers (n 15; 2009 to 2011) and pigs (n 20; 2008 to 2011) in The
Netherlands were included (30) (Table S1).
(v) PCR ribotype reference isolates. For additional context, five PCR ribotype reference C. difficile
genomes representing RT078, RT126, RT033, RT045, and RT066 were included, all of which are genetically
very closely related, sharing the same multilocus sequence type, ST11 (see Table S1 and Fig. S1 in the
supplemental material).
(vi) Four additional genotypes. Four additional C. difficile genotypes were also analyzed phyloge-
netically to contextualize findings in RT078; these were ST35(046) (n 34), ST54(012) (n 54), ST37(017)
(n 64), and nontoxigenic ST26(140) (n 65) (Table S2). These four genotypes underwent detailed study
because they had the highest tetM prevalence after RT078. The isolates came from the Oxfordshire
EIA-positive and EIA-negative, Oxfordshire Infant, and Leeds region isolate collections described above
(8, 29). ST26(140) lacks the toxin-encoding pathogenicity locus and is therefore carried asymptomatically,
providing a naturally occurring “control” for the impact of antimicrobial selection in the absence of
disease.
Genome assemblies. C. difficile genomes were assembled from short reads generated using Illumina
technology (64). Reference-based assemblies were made for genomes belonging to C. difficile clade 5 (i.e.,
RT078 and close relatives) as described previously (65) by mapping reads to the C. difficileM120 reference
genome (66) and for non-clade 5 genomes by mapping reads to the CD630 reference genome (GenBank
accession no. AM180355.1) (66) (clades defined as described in reference 35). De novo assembly was
performed using Velvet (version 1.0.7–1.0.18) (85) and VelvetOptimiser 2.1.7 (67), optimizing kmer size
(k), expected coverage (average kmer coverage of contigs), and coverage cutoff (kmer coverage
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threshold) to achieve the highest assembly N50 value (length of the smallest contig such that all contigs
of that length or less formed half of the final assembly). Reads for unassembled genomes have been
submitted to NCBI under BioProject identifier (ID) no. PRJNA304087 (8) and PRJNA381384 for the Scottish
isolates (accession numbers are provided in Tables S1 and S2).
Identification of antimicrobial resistance determinants. The de novo assemblies were queried
using the BLAST function of BIGSdb (68) to determine whether genes or nonsynonymous point
mutations known to confer resistance to antimicrobials (including fluoroquinolones, tetracyclines, clin-
damycin, and aminoglycosides) were present and to extract the sequences of interest for further analysis.
A list of the resistance gene sequences used to perform the BLAST search (and of their GenBank
accession numbers) is provided (Table 1 and 2). For acquired resistance genes, a minimum level of 90%
nucleotide sequence identity and gene coverage was required. Each unique tetM allele was assigned a
number (allele nucleotide sequences are available at https://pubmlst.org/bigsdb?dbpubmlst_cdifficile
_seqdef&pagedownloadAlleles).
Definition of multilocus sequence types (MLST). Allele sequences used in the C. difficile MLST
scheme (69) were extracted from the de novo assemblies using the BLAST function of BIGSdb (68).
Sequence types (STs) were assigned by querying the MLST database (https://pubmlst.org/cdifficile/).
Phylogenetic analyses. Phylogenetic trees were built on the basis of the assemblies mapped to C.
difficile ST11 reference M120 using the maximum likelihood approach implemented in PhyML version
3.1.17 (with a generalized time-reversible substitution model and the “BEST” tree topology search
algorithm) (70). The trees were then corrected to account for recombination events using ClonalFrameML
(71) version 1.11 (with default settings). The nodes of the trees were dated using the previously estimated
C. difficile evolutionary rates of 1.1 mutation per year (30) for clade 5 STs (including RT078) and of 1.4
mutation per year for all other genotypes (72). The main period of particular interest (from 1990 to 2015)
was allocated the greatest amount of horizontal space in graphical tree representations by compressing
the pre-1990 period, making the trees directly comparable with respect to the post-1990 period. Events
before 1990 are not shown since dating older nodes using a short-term evolutionary rate is problematic
due to the time dependency of evolutionary rates (73). Graphical representations of trees were made
using FigTree version 1.4.2 (74).
A quantitative assessment of clonal expansion(s) within a given phylogeny was performed as
described previously (39) and as implemented previously (8). The evolutionary distinctiveness (ED) score
of each isolate was calculated; the ED score was defined as being equal to the sum, for all branches on
the path from the root to the leaf (isolate), of the lengths of the branches divided by the number of
leaves that they support (39). For a given isolate, a low ED score indicated the presence of close relatives
in the tree, whereas a high ED score indicated their relative absence. ED scores were compared across
various factors using quantile regression statistics analyses, performed using Stata version 14.1 (College
Station, TX, USA).
Data availability. Reads for unassembled genomes have been submitted to NCBI under BioProject
ID numbers PRJNA304087 (8) and PRJNA381384 for the Scottish isolates (accession numbers are
provided in Tables S1 and S2).
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